Soria-Chacartegui, P.; Cendoya-Ramiro, P.; González-Iglesias, E.; Martín-Vílchez, S.; Rodríguez-Lopez, A.; Mejía-Abril, G.; Román, M.; Luquero-Bueno, S.; Ochoa, D.; Abad-Santos, F.
Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron. Pharmaceutics 2024, 16, 1077.
https://doi.org/10.3390/pharmaceutics16081077
AMA Style
Soria-Chacartegui P, Cendoya-Ramiro P, González-Iglesias E, Martín-Vílchez S, Rodríguez-Lopez A, Mejía-Abril G, Román M, Luquero-Bueno S, Ochoa D, Abad-Santos F.
Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron. Pharmaceutics. 2024; 16(8):1077.
https://doi.org/10.3390/pharmaceutics16081077
Chicago/Turabian Style
Soria-Chacartegui, Paula, Patricia Cendoya-Ramiro, Eva González-Iglesias, Samuel Martín-Vílchez, Andrea Rodríguez-Lopez, Gina Mejía-Abril, Manuel Román, Sergio Luquero-Bueno, Dolores Ochoa, and Francisco Abad-Santos.
2024. "Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron" Pharmaceutics 16, no. 8: 1077.
https://doi.org/10.3390/pharmaceutics16081077
APA Style
Soria-Chacartegui, P., Cendoya-Ramiro, P., González-Iglesias, E., Martín-Vílchez, S., Rodríguez-Lopez, A., Mejía-Abril, G., Román, M., Luquero-Bueno, S., Ochoa, D., & Abad-Santos, F.
(2024). Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron. Pharmaceutics, 16(8), 1077.
https://doi.org/10.3390/pharmaceutics16081077
